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2Abstract 
Eukaryotic cells produce proteins continuously through translation, folding and quality 
control within the endoplasmic reticulum (ER). When unfolded proteins accumulate in the 
endoplasmic reticulum the unfolded protein response (UPR) attempts to restore cellular 
function by reducing the load of unfolded proteins. If cellular function is not restored the 
unfolded protein response causes cell death through apoptosis. The only known unfolded 
protein response protein in lower eukaryotes is inositol-requiring enzyme 1 α (IRE1 α). In 
this thesis we investigated whether the kinase domain of inositol-requiring enzyme 1 α 
alone regulates apoptosis or whether the RNase domain is required for apoptotic cell death 
through the unfolded. We found evidence to suggest that inositol-requiring enzyme 1 α 
kinase domain alone does not cause apoptosis. Juxtaposing these results, the kinase domain 
alone causes the presence of phosphorylated proteins that are precursors to apoptosis. Two 
theories are that mutations made to deactivate the RNase domain effected the folding of 
the kinase domain reducing its potency. The second theory is that inositol-requiring enzyme 
1 α RNase domain plays an unknown role in apoptotic cell death in the unfolded protein 
response. 
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71. Introduction 
1.1 ER stress 
Cells have mechanisms to respond to any perturbation and maintain homeostasis, the 
maintenance of the endoplasmic reticulum (ER) is an important function of all cells. The 
ability to respond to perturbations of the ER, ‘ER stress’, is necessary for cell survival; if 
unresolved or under chronic activation will lead to the activation of a signalling network 
culminating in cell death (Ozcan and Tabas, 2012). ER stress has multiple causes. It can be 
caused by increased protein synthesis or misfolding rates exceeding the capacity of 
chaperones ‘client load’ (Ron and Walter, 2007). ER stress can artificially be triggered by 
alteration of calcium stores in the ER lumen or disturbance of the redox balance (Ron and 
Walter, 2007).  
Figure 1.1.1, Overview of ER stress signalling in eukaryotes via the ER transmembrane proteins ATF6, PERK and IRE1 α 
(Kadowaki and Nishitoh, 2013). 
ER stress is sensed by three upstream signalling proteins in multicellular eukaryotes that 
activate a cascade of corrective actions; combined this is known as the unfolded protein 
response (UPR) as shown in Figure 1.1.1, (Tabas and Ron, 2011). The oldest ER stress 
recognition pathway receptor protein is a combined nuclease and kinase called inositol-
requiring 1 IRE1 α. IRE1 α is expressed as two isoforms IRE1 α, systemic, and IRE1 β, which is 
restricted to the gastrointestinal and respiratory tracts (Tabas and Ron, 2011). ER-stress 
transducers such as IRE1 α, become activated when there is an imbalance of unfolded 
proteins and chaperones (Tabas and Ron, 2011). The mechanism for detection of ER stress is 
likely initiated by changes in heterologous protein interactions such as dissociation of 
chaperones such as BiP oligomerization in ER-stressed cells (Ron and Walter, 2007). 
81.2 The unfolded protein response 
The endoplasmic reticulum (ER) is an organelle that contains chaperones and enzymes to 
promote the folding of secretory proteins (Han et al., 2009). A delicate balance exists 
between translation and folding capacity; when translation outpaces folding capacity 
unfolded proteins accumulate and result in ER stress (Han et al., 2009). ER stress is detected 
by three proteins in mammalian cells, IRE1 α, PERK and ATF6, that signal intracellular 
signalling pathways called the unfolded protein response (UPR) (Han et al., 2009). The UPR 
sensors upregulate transcription of genes encoding ER chaperones, oxidoreductases and ER-
associated degradation (ERAD) components (Travers et al., 2000) and phospholipid 
biosynthetic genes (Travers et al., 2000). The UPR exerts a translational block during ER 
stress as a form of adaptive homoeostasis by reducing ER protein load (Harding et al., 2001). 
The UPR upregulates folding capacity and degrades unfolded proteins (Ron and Walter, 
2007). If ER stress reduces, negative feedback leads to waning of the UPR signal and 
recovery of the cell (Merksamer et al., 2008). Alternatively, if misfolded protein stress is too 
great cells are removed through UPR-mediated apoptosis; when large numbers of cells die 
in vital organs this leads to pathological disease (Kaufman, 2002). The mechanism for cell 
fate to choose adaption versus apoptosis through the UPR is unclear due to heavy crosstalk. 
The UPR apoptosis/adaption is likely controlled by the three unfolded protein sensors (Han 
et al., 2009). 
1.3 Structure of IRE1 α
Figure 1.3.1, Diagram of IRE1 α domain organisation. Domain information from NCBI protein blast AAI30408.1 Luminal 
domain 30-270 aa, (STKc) Serine/Threonine kinase 568-833 aa, (RNase) Ribonuclease 836-961 aa. 
The gene ERN1 encodes the type 1 transmembrane ER to nucleus signalling 1 protein also 
known as serine/threonine-protein kinase/endoribonuclease Inositol-requiring 1 (IRE1) 
(Tirasophon, Welihinda and Kaufman, 1998). As shown in Figure 1.3.1, the luminal domain 
of IRE1 α 30-270 amino acids localises within the ER membrane and contains the 
homodimer interface that initiates the formation of oligomers in the presence of unfolded 
proteins in the ER (Aragon et al., 2009; Credle et al., 2005; Zhou et al., 2006). The 
serine/threonine kinase resides at residues 568-833. This domain catalyses the transfer of 
the gamma-phosphoryl group from ATP to serine and threonine residues of target proteins 
including other IRE1 α. The ribonuclease domain resides between residues 835-961 and 
cleaves the exon-intron junctions in the mRNA for the transcription factor controlled by IRE1 
α and catalyses the degradation of RNA reducing the folding demand on chaperones. IRE1 α 
is expressed in all cells and tissues in metazoans and is the only component of the UPR in 
yeast genomes found in eukaryotes (Tirasophon, Welihinda and Kaufman, 1998). Given that 
this protein is conserved from yeast while other UPR proteins are only occur in metazoans, 
it is likely to have a major role in the UPR. 
91.4 mRNA degradation 
During ER stress the UPR uses signalling to regulate ER protein folding capacity as well as 
degrading ER localised mRNA to maintain homoeostasis (Han et al., 2009). ER stress in yeast 
induces oligomerisation and autophosphorylation of IRE1 α luminal domains resulting in the 
assembly of the cytosolic kinase and RNase into a defined three-dimensional structure. The 
oligomer is stabilised by phosphates from autophosphorylation of the kinase domain 
allowing juxtaposition of the RNase domains presumably activating them in yeast 
(Korennykh et al., 2011). 
IRE1 α autophosphorylation also leads to endonucleolytic decay of ER-localised mRNAs 
including those that encode chaperones, via the RNase domain (Han et al., 2009). The 
endoribonuclease (RNase) domain also initiates non-conventional mRNA splicing 
(Korennykh et al., 2011). This splicing leads to production of a transcription factor that 
controls UPR target genes (Korennykh et al., 2011), X-box binding protein 1 (XBP1) mRNA 
splicing results in the active transcription factor XBP1s (Calfon et al., 2002; Yoshida et al., 
2001).  
IRE1 α uses amino acid side chains for catalysis of the RNase activity (Dong et al., 2001). IRE1 
α uses histidine 1061 and tyrosine 1043 residues as general acid-general base pair for 
transition state stabilisation, coordination of the scissile phosphate occurs through 
asparagine 1057 and arginine 1056 (Tirasophon, 2000; Korennykh et al., 2011). IRE1 α can 
specifically cleave anticodon stem-loop (ASL) or tRNA phe and HAC1 XBP1 (Korennykh et al., 
2011). It has been suggested that from the crystal structure of the RNase dimer each 
contain two independent catalytic centres in each monomer simultaneously 
accommodating the two RNA stem-loops (Tirasophon, 2000). While each RNase monomer 
contains separate catalytic apparatus for RNA cleavage, it is presumed that two RNase 
subunits are required to contribute to RNA stem-loop docking (Korennykh et al., 2011). 
Given the conservation of key residues in known homologues between yeast and higher 
eukaryotic IRE1 the process for mRNA degradation is likely to have been conserved as well 
(Korennykh et al., 2011). 
1.5 XBP1 mRNA splicing 
Non-conventional splicing of HAC1 mRNA is seen in yeast and XBP1 mRNA in metazoans by 
cleavage of exons via two conserved sites (Dong et al., 2001), (Lee et al., 2008), (Korennykh 
et al., 2011). IRE1 α recognises conserved sites in XBP1 characterised by a stem containing 
five Watson-Crick base pairs and a seven-residue loop with a consensus sequence 
CNGNNGN (Gonzalez, EMBO J. 1999). The exons are re-joined by tRNA ligase in yeast and in 
metazoans leading to the formation of the active transcription factor XBP1s (Dong et al., 
2001; Lee et al., 2008; Korennykh et al., 2011; Cox et al. 1993, 1996; Sidrauski et al., 1996, 
1997; Calfon et al., 2001; Shen et al., 2001; Yoshida et al., 2001; Lee at l., 2002). Analysis by 
optimal protein RNA area algorithm (OPRA) suggestes interaction between the binding of 
IRE1 α and XBP1 mRNA (Korennykh et al., 2011). OPRA suggests that there is a single RNA 
binding site at the centre of the RNase dimer that interacts with XBP1 mRNA with the rest of 
the surface predicted to be unlikely to interact with RNA (Tirasophon, 2000). The binding 
site properties are likely due to electron density at the core. This is formed of eight residues 
10
located proximal to the substrate binding site contribute to the acid base catalysis leading to 
the formation of the 2’, 3’-cyclic phosphate bond (Korennykh et al., 2011). IRE1 α therefore 
has two functions in vivo requiring RNase domain, initiating XBP1 mRNA splicing through 
site-specific cleavage and ER-localised mRNA decay.
1.6 Kinase activity 
The use of kinase inhibitors has been shown to activate RNase function, bypassing 
autophosphorylation through an alternative route that results in XBP1 splicing but does not 
promote mRNA decay or apoptosis (Han et al., 2009). It is believed that cell fate between 
apoptosis or survival is dependent on either kinase or RNase activity (Han et al., 2009). 
Evidence suggests initial kinase activation translates to downstream effects that restore 
homeostasis and promote survival. Persistent activation of IRE1 α kinase domain signal 
inability to adapt to stress and trigger cell fate switch to apoptosis (Han et al., 2009). Under 
this hypothesis an active kinase/RNase-dead IRE1 α mutant should retain the cytotoxic 
ability of WT (Wild Type) IRE1 α, perhaps more so due to the lack of XBP1s effects. As IRE1 α 
has both apoptotic and survival components, loss of the RNase domain should remove the 
survival processes resulting in increased chances of apoptosis. Han et al., 2009 produced 
mutants with key mutations in the RNase domain, K907A and N906A. These mutants should 
have exhibited active kinase/RNase-dead, although these mutants did not induce apoptosis. 
It is therefore suggested that apoptotic signals from WT IRE1 α require active RNase as well 
as kinase to induce apoptosis (Han et al., 2009). Paradoxically the results of Han et al., 2009 
have also suggested that RNase activity of IRE1 α leads to effectors of both survival and 
apoptosis outputs.  
Although mutants K907A and N906A suggest active kinase/RNase-dead IRE1 α is unable to 
induce apoptosis, given that the RNase and kinase domains are adjacent, mutation may 
alter three dimensional structure and function of IRE1 α. Continuing to produce mutations 
in key RNase residues might produce an active kinase/RNase-dead IRE1 α mutant with the 
wild type three dimensional structure. 
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1.7 JNK activation via ASK1 
Figure 1.7.1, Overview of IRE1 α intracellular stress signalling pathway caused by prolonged ER stress (Kadowaki and 
Nishitoh, 2013). This diagram shows the two outcomes caused by IRE1 α activation, cell survival or apoptosis. P-IRE1 α 
cleaves XBP-1 pre-mRNA resulting in the active XBP-1s a transcription factor that interacts with chaperones to regulate 
gene expression resulting in reduced ER stress and cell survival. If ER stress is maintained apoptosis is caused by activation 
of the TRAF2 pathway though ASK1 and JNK. 
In diseases such as Huntington, spinocerebellar ataxias and diabetes mellitus the 
accumulation of polyQ fragments from mutant genes forms aggregates in the 
cytoplasm/nucleus causing a toxic effect that leads to cell death (Kakizuka 1998; Paulson et 
al. 2000). PolyQ induces ER stress leading to IRE1 α dimerization, ER stress also was shown 
to induce TRAF2–ASK1 complex formation that leads to downstream signalling that 
activates JNK as shown in Figure 1.7.1, (Nishitoh, 2002). ASK1 therefore plays a role 
mediating proteasome dysfunction and ER stress-induced neuronal cell death, an important 
role in the neuropathological alterations occurring in polyQ diseases (Nishitoh, 2002). ASK1 
plays essential roles in stress-induced apoptosis, ASK1 deficient mice show suppressed TNF 
and H2O2 induced apoptosis (Tobiume et al. 2001), with neurons derived from ASK1−/− mice 
showing resistance to ER stress (Nishitoh, 2002). ASK1 has been shown to only associate 
with IRE1 α in the presence of TRAF2, although this evidence was obtained through 
overexpression and has not be confirmed in vivo. It is possible that ER stress induces the 
formation of IRE1 α -TRAF2-ASK1 complex on the ER outer membrane leading to the 
downstream ASK1-JNK pathway through TNF oxidative stress-induced JNK activation and 
apoptosis (Ichijo et al. 1997; Saitoh et al. 1998; Tobiume et al. 2001). Apoptosis signal-
regulating kinase ASK1 has shown experimental evidence to suggest that it directly interacts 
with TNF receptor-associated factor 2 TRAF2 (Nishitoh et al. 1998). JNK is activated by 
mammalian mitogen-activated protein kinase (MAPK) kinase kinase (MAPKKK) the research 
community assume that active IRE1 α triggers a TNF signaling pathway TRAF2–ASK1–
SEK1/MKK4–JNK cascade (Nishitoh et al. 1998). Although JNK activation is linked to IRE1 α -
TRAF2-ASK1, ASK1 negative cell lines still have residual JNK activation by TRAF2 therefore 
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there may be a redundant pathway involving GCK/GCKR– MEKK1 (Yuasa et al. 1998). 
Consistently, TNF-induced JNK activation was partially, but not completely, lost in ASK1−/− 
mutants this shows that JNK activation can be activated via redundant pathway but ER 
stress induced activation is highly specific to ASK1 pathway (Nishitoh, 2002). Therefore JNK 
activation can be caused without the ASK1 pathway, although the ER stress activation and 
apoptosis of interest is specific to IRE1 α pathway. 
The results of (Urano, 2000) suggest that ER stress induced IRE1 α kinase activation is 
important in the recruitment of TRAF2 while endonuclease activity is dispensable. ER stress 
through a cascade leads to the activation of c-jun amino-terminal kinases, IRE1 α -/- 
fibroblasts had impaired JNK activation during ER stress therefore IRE1 α is a regulator in 
JNK activation (Urano, 2000). The cytoplasmic domain of IRE1 α binds TRAF2 adapter 
protein that couples plasma membrane receptors to cause JNK activation by stress-
activated protein kinases (SAPKs) NH2-terminal kinases of which are a family of signal 
transduction proteins that are activated under a range of stimuli (Urano, 2000). JNKs 
regulate gene expression though a range of transcription factors cJUN ATF3 active 
components of anti-apoptotic activity (Urano, 2000). Deletion of TRAF2 inhibits JNK 
activation by TNF, TRAFs appear to be specifically important in the activation of kinase 
cascade culminating in JNK phosphorylation (Urano, 2000). The IRE1 α -mediated apoptosis 
therefore requires both IRE1 α kinase activity and AK1/TRAF2 interaction for ER stress 
mediated apoptosis. 
1.8 IRE1 α Fv2E-Chimera 
As discussed in section 1.1 cells have the ability to respond to endoplasmic reticulum stress 
through three upstream signalling proteins in multicellular eukaryotes (Han et al., 2009). For 
this project, we wish to investigate IRE1 α as this protein has a conserved counterpart in 
yeast while yeast has no known counterpart protein for AFT6 or PERK (Korennykh et al., 
2011). Investigation into the function of IRE1 α has often been done through yeast HAC1. As 
yeast does not possess ATF6 or PERK, HAC1 can be activated in isolation to study its effects 
(Korennykh et al., 2011). Although ER stress can artificially be triggered in the lab by 
alteration in calcium stores in ER lumen or disturbance to the redox balance. Disturbances 
using these methods would also cause the activation of ATF6 and PERK (Ron and Walter, 
2007). 
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Figure 1.8.1, Activation of IRE1 α through activation Bip in response to unfolded proteins. Bip binds to unfolded protein and 
interacts with IRE1 α luminal domain. The Bip – IRE1 α interaction results in dimerization of IRE1 α cytoplasmic domains 
resulting in the active IRE1 α dimer.
As described in Fig 1.8.1, IRE1 α naturally interacts with Bip in the presence of unfolded 
proteins. Dimerization of the luminal domains results in phosphorylation of the cytoplasmic 
domains. To explore IRE1 α activation in isolation IRE1 α Fv2E-chimera has been created.  
The Fv2E system allows for ER stress activation specific to IRE1 α without the use of stress 
mimetic drugs (Lu et al., 2004a) (Spencer et al., 1993). Through the fusion of the ERN1 
cytoplasmic effector domain to a polypeptide containing two FK506 binding domains shown 
in Fig 1.8.2, (iDimerize, Takara). This results in a soluble cytoplasmic protein that can 
dimerise in the presence of a synthetic small organic molecule AP20187. The Fv2E system 
has been used to study PERK signalling (Deng et al., 2004), and IRE1 α (Watson., 2017). The 
Fv2E IRE1 α mutant dimerization has been shown to be sufficient for XBP1 splicing in the 
absence of ER stress (Back et al., 2006). Watson 2017 PhD thesis produced a system that can 
specifically activate IRE1 α though AP20187. Through this system we hope to investigate the 
downstream effects of the IRE1 domains in isolation from ATF6 and PERK by causing 
dimerization of Fv2E IRE1 α through exposure to AP20187. 
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Figure 1.8.2, Comparison of wild type IRE1 α and Fv2E IRE1 α domains. The Fv2E mutant has the ER luminal and TM 
domains removed and replaced with two FK506 binding domains. This mutant is a soluble cytoplasmic protein that can 
dimerise in the presence of a synthetic small organic molecule AP20187 
1.9 T-RexTM mammalian expression system 
Figure 1.9.1, Diagram of T-REx induction of IRE1 α. Cells produce the protein TetR from the TetR gene. TetR forms a dimer 
and binds to TetO2 sequence downstream of TATA box and upstream of IRE1 α. Tetracycline introduced into the medium 
binds to TetR dimer, tetracycline prevents the binding of TetR to the Tet02 binding sites resulting in the gene being 
expressed.  
The IRE1 α gene (ERN1) was cloned into multiple cloning sites of the inducible expression 
vector. The plasmid is co-transfected with a regulatory plasmid (pOG44) into mammalian 
cells. After transfection cells treated with tetracycline induce transcription of the gene of 
interest. The T-RExtm system allows tetracycline regulated expression in mammalian cells 
using regulatory elements from the E. coli Tn10-encoded tetracycline (Tet) resistance 
operon (Hillen and Berens, 1994; Hillen et al., 1983). In this system tetracycline binds to the 
Tet repressor and depresses the promoter controlling expression of the gene of interest 
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(Yao et al., 1998). 
Using this system IRE1 α gene will be repressed in the absence of tetracycline and induced 
in the presence of tetracycline. Expression of the IRE1 α gene is controlled by the CMV 
promoter (Andersson et al., 1989; Boshart et al., 1985; Nelson et al., 1987). The promotor 
is next to two tet operator 2 (TetO2) inserted in tandem. In the absence of tetracycline, the 
repressor forms a homodimer with high affinity to the TetO2 sequences. Binding of the Tet 
repressor homodimers to TetO2 represses IRE1 α; tetracycline binds to Tet repressor 
homodimer causing conformation change rendering it unable to bind to Tet operator. The 
Tet repressor complex dissociates from the tet operated allowing induction and 
transcription for the IRE1 α gene as detailed in Figure 1.9.1. 
1.10 Project objectives 
This project explored the kinase domain of IRE1 α and if the kinase domain alone controls 
apoptotic cell death. To do this we attempted to create an RNase deficient kinase active 
Fv2E IRE1 α mutant. The project explored the domain activity of three IRE1 α mutants 
created as part of a Watson, Jamie, Nicholas (2017) PhD thesis. We also attempted to create 
new IRE1 α mutants based on mutations from Tirasophon et al., 2000. 
We confirmed mutant IRE1 α expression using the T-RExtm system and Western blotting of 
cell lysate as described in 1.9. We investigated if these mutations have lost the RNase 
activity of IRE1 α through the cleavage of XBP1. We extracted RNA before converting it to 
cDNA using XBP1 primers and running it on an agarose gel for visualisation under ultraviolet 
light. To do this we used the wild type Fv2E IRE1 α to determine the timeframe of XBP1 
splicing before using the splicing assay to determine the RNase activity of each mutant. For 
mutants that no longer show RNase activity through XBP1 splicing assay, we explored kinase 
activity through Western blotting using the T-REx and Fv2E systems. 
Mutants created that were kinase active and RNase deficient, were tested to confirm 
apoptotic capability through an MTT test for cell viability when compared to WT Fv2E IRE1 α. 
To define the activity of IRE1 α kinase activity we explored markers for cell death through 
apoptosis like PARP-1 and P-JNK.  
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2. Materials 
2.1 Materials 
The following section lists all materials used for experimentation in this thesis. Solutions are 
prepared in type I laboratory H2O (resistivity 18 MΩ cm, total organic carbon < 1 ppb, 
microorganisms < 1 cfu/ml, particles < 0.05 μm diameter) generated by the NANOpure 
Diamond UV/UF TOC water purification system and sterilized by autoclaving (121°C, 20 – 30 
min).  
2.2 Oligodeoxynucleotides for Homo sapiens genes 
Table 2.2 Oligodeoxynucleotides 
Name Purpose  Sequence  
H9406
Forward 
D847A 
mutation + 
BssHII cut site CAGGGATTCCTTTTCTATTCGCGCGCTCACGTCCTGGAAGAAC
H9407
Reverse 
D847A + 
BssHII cut site GTTCTTCCAGGACGTGAGCGCGCGAATAGAAAAGGAATCCCTG
H9408
Forward 
G923A 
mutation + 
Nhe1 cut site TCGGGGAGGGACGCTAGCGTCTCCCGC 
H9409
Reverse 
G923A 
mutation + 
Nhe1 cut site GCGGGAGACGCTAGCGTCCCTCCCCGA 
H9410
Forward 
D927A 
mutation + 
Sac2 cut site AGCACACGAAGTCCGCGGGGAGGGACCC 
H9411
Reverse 
D927A + Sac2 
cut site GGGTCCCTCCCCGCGGACTTCGTGTGCT 
H9412
Forward 
Y932A + NsbI 
cut site GGGAAGCGAGACGTGAATGCGCACACGAAGTCGTCGG 
H9413 Reverse Y932A 
+ NsbI cut site CCGACGACTTCGTGTGCGCATTCACGTCTCGCTTCCC 
3245L XBP1-probe, 5' CTGCTGATTCTTTGTCAGCG 
3246L XBP1-probe, 3' TAGCATTAACAGTGACACGG 
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2.3 Antibodies for Western blotting  
Table 2.3 Antibodies 
2.4 Mammalian cell lines 
Table 2.4 Mammalian cell lines 
Name Obtained from Culture medium 
Flp-In T-REx HEK 293. Human 
embryonic kidney  
M. Cann, Durham 
University  
DMEM, 10% FBS, 2 mM 
L-glutamine 
Flp-In T-REx HEK293 with Fv2E-
IRE1 α (K599A)stably integrated  
Dr. David Cox, Durham 
University  
DMEM, 10% FBS, 2 mM 
L-glutamine + 15 μg/ml 
blasticidin + 100 μg/ml 
hygromycin B  
Flp-In T-REx HEK293 with Fv2E-
IRE1 α stably integrated 
Dr. David Cox, Durham 
University  
DMEM, 10% FBS, 2 mM 
L-glutamine + 15 μg/ml 
blasticidin + 100 μg/ml 
hygromycin B 
Name  
Primary / 
secondary Host  Polyclonal/Monoclonal Source  
Product 
Number  
Anti-HA Primary Rabbit Polyclonal  Sigma-Aldrich H6908 
anti-IRE1  
α Primary  Rabbit Polyclonal Abcam ab37073 
anti-IRE1 
α , 
phospho-
S724 Primary  Rabbit Monoclonal [EPR5253] Abcam ab124945 
anti-JNK, 
phospho-
T183/Y185 Primary  Rabbit Monoclonal [81E11] Cell Signalling 4668S 
anti-PARP1 Primary  Rabbit Polyclonal Cell Signalling 9542S 
anti-HA Primary  Mouse Monoclonal [12CA5] Roche 1583816 
Normal 
mouse IgG Secondary Mouse Polyclonal 
Santa Cruz 
Biotechnology sc-2025 
Normal 
rabbit IgG Secondary Rabbit Polyclonal 
Santa Cruz 
Biotechnology sc-2027 
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2.5 Cell culture reagents for tissue culture  
Table 2.5 Cell culture reagents 
2.6 Reagents  
Table 2.6 General use reagents 
Name  Product Number  Company  
5x First strand buffer  Y02321  Thermo Fisher Scientific  
5x green GoTaq Flexi buffer  M891A  Promega  
Acetic acid (HOAc)  A/0360/PB17  Thermo Fisher Scientific  
Agarose  MB1200  Melford, Ipswich, UK  
Ampicillin  BIA0104  Apollo Scientific,  
β-Mercaptoethanol  M-6250  Sigma-Aldrich  
Bovine serum albumin  A2153-50G  Sigma-Aldrich  
Complete mini protease inhibitors  11836 153 001  Roche  
D-Glucose G/0500/61 Thermo Fisher Scientific  
Ethidium bromide  E1510-10ML  Sigma-Aldrich  
Glycerol  G/0650/17 Thermo Fisher Scientific 
GoTaq Hot Start Polymerase 5 u/μl  M5001  Promega  
GoTaq G2 flexi polymerase 5 u/μl  M7801  Promega  
Glycine BP381-1  Thermo Fisher Scientific 
LB-Agar LENNOX  LBX0202  Formedium, King’s Lynn, 
Name  Supplier  Product 
number  
Minimal essential medium  Sigma Aldrich  M2279  
Dulbecco’s modified Eagle’s medium with pyruvate  Sigma Aldrich  D6546  
Dulbecco’s modified Eagle’s medium without pyruvate  Sigma Aldrich  D5671  
Fetal bovine serum  Biosera, 
Boussens, France  
S1830  
200 mM L-Glutamine solution  Sigma Aldrich G7513  
Penicillin (10000 U/ml)/streptomycin(10 mg/ml)  Sigma Aldrich  P4333  
Trypan blue solution 0.4% (w/v) in 0.81% sodium 
chloride and 0.06% potassium phosphate.  
Sigma Aldrich  T8154  
Trypsin 0.25% (w/v)  Life Technologies 
Ltd  
25200- 056  
Hygromycin B (50 mg/mL) Thermofisher 
scientific 
10687010 
Tetracycline hydrochloride Sigma Aldrich  T7660 
Blasticidin S HCl (10 mg/mL) Thermofisher 
scientific 
A1113902 
AP20187 Clontech 635058 
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UK  
LB-Broth LENNOX  LBX0102  Formedium  
Methanol M/4000/PC17 Thermo Fisher Scientific 
Oligo(dT)15 500 μg/ml  C1101  Promega  
PhosSTOP  4906837001 Roche  
Propan-2-ol  P/7490/17  Thermo Fisher Scientific  
RNasin Ribonuclease Inhibitor 20-40 
u/μl  N22111  Promega  
Tris(hydroxymethyl) methylamine 
(Tris)  T/3710/60  Thermo Fisher Scientific  
Tween20 P1379-500 Sigma-Aldrich 
Tetracycline 87130 Sigma-Aldrich 
2.7 Special consumables  
Table 2.7 Special consumables  
Name  Product Number  Company  
6-well plate, adherent  83.1839 
Sarstedt, Nümbrecht, 
Germany  
Polyvinylidene difluoride (PVDF) Transfer 
Membrane (0.45μm pore size)  RPN303F  GE Healthcare  
CL-X Posure film 34091 Thermo Fisher Scientific 
Tissue culture dish 58 cm2 Adherent  83.1802 Sarstedt  
Tissue culture flask 175 cm2 Adherent  83.1812 Sarstedt  
Tissue culture flask 75 cm2 Adherent  83.1811 Sarstedt  
Tissue culture flask 25 cm2 Adherent  83.181 Sarstedt  
Tissue culture flask 175 cm2 Suspension  83.1812.502  Sarstedt  
Tissue culture flask 75 cm2 Suspension  83.1811.502  Sarstedt  
Tissue culture flask 25 cm2 Suspension  83.1810.502  Sarstedt  
Microtest Plate 96 Well,F 82.1581.001 Sarstedt  
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2.8 Commercially available kits 
Table 2.8 Commercially available kits 
Name  
Product 
Number  Company  
GenElute plasmid mini prep kit PLN10 Sigma-Aldrich 
QuikChange II XL Site-Directed Mutagenesis 
Kit 200521 Agilent Technologies 
Amersham ECLTM Western blotting detecting 
reagents  RPN2009  
GE Healthcare, 
Buckinghamshire, UK  
DCTM Protein assay reagent A  500-0113  BIORAD  
DCTM Protein assay reagent B  500-0114  BIORAD  
DCTM Protein assay reagent S  500-0115  BIORAD  
EZ-RNA kit (solution A and B)  K1-0120  Geneflow, Lichfield, UK  
GeneRuler 1 kb DNA ladder  SM0311  Thermo Fisher Scientific 
GeneRuler DNA ladder mix  SM0331  Thermo Fisher Scientific 
GoTaq qPCR Master Mix  A6002  
Promega, Southampton, 
UK  
jetPRIME ® DNA Transfection Kit 114-07  
Polyplus transfection, 
Illkirch, France  
PageRuler Plus prestained protein ladder  26619 Thermo Fisher Scientific 
Pierce ECL Western blotting substrate  32209 Thermo Fisher Scientific 
Tetro cDNA synthesis kit  BIO-65042  Bioline, London, UK  
GenElute High Performance (HP) Plasmid 
Maxiprep NA0300 Sigma-Aldrich 
Complete protease inhibitors  1.1836E+10 
Roche, Basel, 
Switzerland  
2.9 Growth media containing ampicillin 
2.9.1 LB agar ampicillin plates 
35 g of LB agar Lennox (Formedium) for every 1000 mL dH2O and was mixed. The mixed 
medium was added to a flask, covered with foil and autoclaved. When the flask was cool, 
ampicillin at a 1:1000 dilution was added under sterile procedure to giving a concentration 
of 50 µg/ml. 25 ml of the solution was plated on to petri dishes(SLS 9CM Petri dish single 
vent) using sterile procedure, when solid the petri dishes were wrapped with Para film, 
store at 4˚C. Dry LB plates in an incubator at 37˚C for 1 h or until dry. 
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2.9.2 LB agar broth 
20 g LB broth was added for every 1000 ml dH2O, mixed in a flask and autoclaved (prestige 
medical clinical autoclave 9 L). When the broth was cool, ampicillin was added at a 1:1000 
dilution. Final concentration of the solution was 50 µg/ml. 
2.10 Sequence analysis
Plasmid DNA sequences were sequenced by DBS Genomics Durham and analysed using 
SnapGene software version or 3.0.3 pDRAW32 revision 1.1.131. 
2.11 Sterilisation of equipment 
Solutions and glassware were autoclaved at 121°C for 20 min and 1 atmosphere.  
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3 Methods 
3.1 Bacterial culture 
All work with E. coli was carried out beneath a Bunsen burner flame on a bench that had 
been sterilised with 70 % (v/v) ethanol. The orifices of any tubes, flasks or bottles that were 
opened during bacterial culture were flamed using the Bunsen burner before and after use.  
3.1.1 Reviving bacterial cultures 
Cultures were removed from -80˚C, a small sample was chipped from the frozen stock using 
a sterile pipet on to a LB agar ampicillin plate (2.9.1) Bacteria were spread on LB agar plate 
using sterile procedure, incubate overnight in 37˚C. 
3.1.2 Growth of E. coli Cultures 
4 ml LB-broth containing the appropriate concentration of antibiotics to select for the 
desired bacteria were inoculated with cells from a single E. coli colony. The E. coli were 
incubated at 37 oC with shaking at 225 – 250 rpm overnight. The cells were collected by 
centrifugation at 12,000 g for 1 min at room temperature and washed three times with 1 ml 
of LB-broth. The pellets were resuspended in LB broth and diluted 1:100 into LB-broth 
containing the appropriate concentration of antibiotics. Cultures were incubated at 37 oC 
with shaking at 225 – 250 rpm overnight. 
3.1.3 Snap freezing bacterial cultures 
1 ml of 30 % (v/v) glycerol was mixed with 1 ml of fresh overnight culture in a 2 ml cryo-vial 
and flash-frozen in liquid nitrogen before storage at -80 ˚C.  
3.2 Protocols for the preparation/use of DNA 
3.2.1 PCR primer design 
Site directed mutagenesis was applied using polymerase chain reaction (PCR) and 
QuickChange Lightning Multi Site-Directed Mutagenesis Kit from Agilent Technologies.  
QuickChange primers were designed on Agilent website and then synthesised by 
Eurogentec. (For primer sequences see materials), primers were dissolved in double distilled 
water to a concentration of 100 µM and stored at -20˚C. 
3.2.2 Plasmid concentration analysis 
Concentrations was measured using a NanoDrop ND-1000 spectrophotometer and ND-1000 
software version 3.2.1. Protocol specific for this machine can be found on the 
manufacturer's website. 
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Or concentrations were measured using SpectraMax 190 Microplate Reader and softmax 
pro software with a wavelength of 260 nm. 1 µl of plasmid was added to 49 µl if dH2O into a 
microplate. The plate was read by the SpectraMax 190 Microplate reader against a control 
of sterilised water. 
3.2.3 DNA Agarose Gel Electrophoresis  
0.3-3.0 g of electrophoresis-grade agarose were placed into an Erlenmeyer flask along with 
30-150 ml of TAE buffer and melted with heating. The DNA samples were mixed with 6x 
DNA loading dye and added to the wells alongside a GeneRuler DNA ladder. The gel was run 
at 120 V and the DNA was visualized at 312 nm, 0.120 J/cm2 using a UV transilluminator. 
3.2.4 Preparation of ultracompetent XL10-Gold Cells 
The XL10-Gold cells (Agilent Technologies) were removed from storage at -80˚C and slowly 
thawed in ice and 35 µl of cells were aliquoted into cooled 1.5 ml microcentrifuge tubes. 
Once thawed on ice 1.5 µl XL 10-Gold ß-Mercaptoethanol (ß-ME) was added and mix 
(Agilent Technologies). The mixture was gently swirled every two min for ten min while still 
on ice. 
3.2.5 QuickChange Lightning Multi Site-Directed Mutagenesis PCR 
16.75 µl double-distilled H2O was added to a test tube. To this mixture the following 
regents were added, 2.5 µl 10x Quickchange Lightning Multi reaction buffer, 0.75 µl 
Quicksolution, 1 µl of diluted ds-DNA template, 1 µl of each diluted mutagenic primer, 1 µl 
dNTP mix, 1 µl QuickChange Lightning Multi enzyme blend. The complete reaction mixture 
was placed in a PCR thermal cycler, and used these modified thermal cycling parameters. 
Reaction rates 
Initial denaturation 95.0°C 2 min
Denaturation 95.0°C 20 s
Annealing 55.0°C 30 s x 30 cycles
Extension 65.0°C 3.5 min
Final extension 65.0°C 5 min
Hold   4.0°C ∞
The cycler maintained temperature at 5˚C until sample was removed for storage.
Once PCR reaction was complete, the product was cooled on ice and then stored at -20˚C. 
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3.2.6 Digestion of methylated parental DNA 
The cooled quick-change PCR product had 1.5 µl of DpnI restriction enzyme (Agilent 
Technologies) added directly to the thin-wall PCR tube. PCR product was placed in a 
incubator for 10 min at 37 ˚C, the digested PCR product was stored at -20 ˚C. 
3.2.7 Introduction of plasmid to XL10-Gold cells
Introduction followed modified manufactures protocol, 
(http://www.agilent.com/cs/library/usermanuals/Public/200314.pdf) modification below. 
The PCR tube was removed from the incubator, 5 µl of the digested plasmid was added 
gently but directly to the Eppendorf tube containing 35 µl of XL10-Gold cells. The mixture 
was incubated on ice for thirty minutes, during this incubation a water bath was heated to 
42 ˚C, after incubation finished the Eppendorf tube was heat shocked for 30 seconds in the 
water bath then put back on to ice for two minutes. 
500 µl of SOC medium (2.13) was added to the transformed cells, the sample was incubated 
in an incubator at 37˚C and rotated at 220 rpm for an hour. 
3.2.8 Plating transformed cells 
The transformed cells were removed from the incubator, using aseptic technique 200 µl of 
cells was plated and spread on kanamycin selective LB agar plate (2.9.1). The plate was 
incubated overnight at 37˚C to allow growth of transformed colonies. The transformed 
culture of cells was stored at 4˚C and re-plated if no colonies formed. 
3.2.9 Culturing bacteria 
Colonies were selected using autoclaved tooth pick and sterilised forceps and placed into a 
bacterial culture tube and 4 ml LB ampicillin broth (2.9.2.), Incubate 37˚C 250rpm overnight 
(infors ht shaker). 1 ml of overnight culture was pelleted, supernatant was aspirated and 
discarded, the pellet was re-suspended in 1 ml of dH2O. Pellet was washed in this way three 
times. Re-suspend pellet in sterile water and add to 100mL LB broth with 100 µl ampicillin 
(2.9.2.) in a 250 ml flask, incubate overnight at 37˚C 250 rpm (infors ht shaker). 
The 100 ml overnight culture was decanted from its flask into 250 ml 8 oz centrifuge tubes 
(Nalgene) and placed on ice. The culture was pelleted in a Beckman coulter Avanti j-26 XP 
centrifuge at 4800 g 4˚C for 15 minutes with JLA 16.250 rotor. The supernatant was 
aspirated and discarded, the pellet was stored at -20˚C. 
3.2.10 Plasmid DNA midiprep from E. coli (Sigma-Aldrich) 
Plasmid DNA midipreps were carried out using Sigma’s GenEluteTM HP Plasmid Midiprep Kit 
(2.8 Commercially available kits). Please refer to manufactures instructions for protocol.
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3.2.11 Restriction analysis
Prepare on ice an Eppendorf tube containing, dH2O to the final volume 20 µl, 500 ng 
plasmid DNA, 0.5 μl BGLII and 2μl of 10x buffer O. The tube was incubated 37 ̊C for one hour 
in a water bath. The mixture was electrophoresed on an agarose gel as described in 3.2.3. 
The gel was loaded with 5 µl GeneRuler 1 kb DNA ladder  (Thermo Scientific), 20 µl of each 
digested plasmid + 4 µl 6X loading dye (thermo scientific) and 1 µl of each undigested 
plasmid mixed with 4 µl water and 1 µl dye (Thermo Scientific). The DNA was then visualized 
at 312 nm, 0.120 J/cm2 using a UV transilluminator. 
3.3 Protocols for mammalian cell experiments 
3.3.1 Mammalian Cell Culture 
All cell cultures were maintained in a medium of DMEM +10% FBS. Antibiotic resistant lines 
were cultured in DMEM, 10% FBS, 2 mM L-glutamine + 15 μg/ml blasticidin + 100 μg/ml 
hygromycin B (2.4). Cells were incubated at 37 °C with 5 % (v/v) CO2 at 95 % humidity. All 
work was done in a laminar flow cabinet. Equipment, including the flow hood, was sterilised 
with 70 % (v/v) ethanol before use. 
3.3.2 Reviving mammalian cells
Cells were removed from liquid nitrogen stores at -130˚C. Cells were thawed in 37˚C water 
bath. In a cell culture fume hood using sterile procedure cells were added to 9 ml DMEM + 
10 % FBS + 2 mM L-Glutamine (100 μg/ml hygromycin B + 15 μg/ml blasticidin if appropriate) 
in an adherent culture flask. Cells were cultured at 37 °C with 5 % (v/v) CO2 at 95 % humidity. 
3.3.3 Cell Counting with a Haemocytometer 
Cells were detached and resuspended in the appropriate medium as described above. A 100 
μl sample of the cell suspension was aliquoted into a sterile 1.5 ml microcentrifuge tube and 
mixed in a 1:1 ratio with 0.4 % (v/v) trypan blue in 0.9 % (w/v) NaCl by gently pipetting up 
and down four times. The haemocytometer was cleaned using 70 % (v/v) ethanol and the 
cover slip was attached using a few droplets of water from a 10 ml pipette. ~ 10 μl of the 
cell suspension was loaded underneath the cover slip using the loading groove and left to 
settle for 2 min. The counting grids were visualised at a 100x magnification and the cells 
within a square of area 0.04 mm2 were counted on both of the counting grids so that the 
average number of cells per ml of medium could be calculated using the following formula: 
Cells/ml = 2 x average count per square x dilution factor x 104.
3.3.4 Maintaining mammalian cell lines 
Medium was removed from flask, cells were washed with 5ml PBS (Gibco) followed by 0.5 
ml Trypsin-EDTA (Gibco) wash. The flask was placed into the incubator 37 °C with 5 % (v/v) 
CO2 at 95 % humidity until cells detached, once loose cells were re-suspended in 10 ml 
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DMEM + 10 % FBS + 2 mM L-Glutamine. Cells were split into new in 75 cm2 adherent cell 
flask with fresh medium (100 μg/ml hygromycin B + 15 μg/ml blasticidin if appropriate) with 
a total volume of 10 ml.  
3.3.5 Transfection of mammalian cells (jetPRIME®)
HEK 293 Flp-In Trex cells were split as described in 3.3.4 and counted as described in 3.3.3, 
80,000 cells were plated into 2 ml medium in a 6 well plate and cultured overnight. In a 
sterilise Eppendorf tube add 500 µl jetPRIME ® buffer, add 2 µg of DNA at 9:1 ratio of 
pOG44 to desired plasmid DNA and 4 µl of jetPRIME® reagent. The Eppendorf tube was 
briefly vortexed and incubated for 10 min at room temperature. The contents were gently 
dropped onto the wells of the 6 well plate in the cell culture fume hood. Medium was 
replaced with medium containing 50 µg/ml hygromycin B for 2 d, then increased 
hygromycin B concentration to 100 µg/ml; maintain 15 µg/ml blasticidin throughout. Cells 
were incubated at 37 °C with 5 % (v/v) CO2 at 95 % humidity. 
3.3.6 RNA extraction (GeneFlow)
Cells were split as described in 3.3.4 and counted using 3.3.3. 1x106 cells were seeded into 
10 cm culture dish, Cultured overnight at 37 °C with 5 % (v/v) CO2 at 95 % humidity.  
We used EZ RNA kit (Bioind) to extract RNA following the manufacture protocol 
(http://www.bioind.com/ez-rna-total-rna-isolation-kit/). 
We removed the medium and wash with room temperature PBS. We lysed the cells directly 
to culture dish using 0.5 ml denaturing solution. The cells were scraped off and collected in 
an Eppendorf tube and 0.5 ml extraction solution were added. The mixture was shaken for 
15 min and stored at room temperature for 5 min. Centrifuge at 12,000 g for 15 min at 4˚C. 
Transfer upper phase to fresh tube. Add 0.5ml ice cold isopropanol per 0.5 ml denaturing 
solution. Invert tube 5 times. Store overnight at -20˚C to increase yield. Centrifuge for 30 
min at 4˚C 12,000 g. Aspirate supernatant. Add 1 ml ice-cold 75 % ethanol (v/v) votex briefly. 
Centrifuge 15 min at 4˚C and 12,000 g. Aspirate supernatant. Centrifuge tubes at 4˚C, 12,000 
g for 10-15 s and aspirate supernatant. Air-dry pellet for 5 min. Dissolve pellet in 20 µl DEPC 
H2O. Store at -80˚C. 
3.3.7 cDNA synthesis 
To produce cDNA we followed Tetro cDNA synthesis kit protocol. 
(https://www.bioline.com/au/tetro-cdna-synthesis-kit.html) 
3.3.8 XBP1 Splicing assay 
In a sterile, nuclease free PCR tube 19 µl H2O was added, to this test tube the following 
reagents were added, 10 µl 5 x Green GoTaq flexi buffer, 3 µl 25 mM MgCl2, 5 µl 2 mM 
dNTPs in 1 mM Tris·HCl, pH 8.0, 5 µl 10 µM forward primer F2, 5 µl 10 µM reverse primer R2, 
2.5 µl cDNA from above and 0.5 µl 5 U/µl GoTaq hot start polymerase. 
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The following cycling parameters were used: 
Initial denaturation 94.0°C 2 min
Denaturation 94.0°C 1 min
Annealing 59.0°C 1 min x 35 cycles
Extension 72.0°C 30 s
Final extension 72.0°C 5 min
Hold   4.0°C ∞
The whole 50 µl reaction was electrophoresed at 100 V for 1 h on a 2 % (w/v) agarose gel 
with 1x TAE as a running buffer containing 1 µg/ml ethidium bromide (p018). The Bands 
were visualised under UV. 
3.3.9 MTT assay for cell viability (Mosmann, 1983)
To assess the number of living cells post-treatment an MTT (3-[4,5-Dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide; Thiazolyl blue) colorimetric assay was used. ~80,000 cells 
were seeded in 9 ml DMEM + 10 % FBS + 2 mM L-Glutamine 100 μg/ml hygromycin B + 15 
μg/ml blasticidin.100 μl was seeded into the cavities of a 96 well tissue culture plate and left 
overnight (20% confluency). Cells were treated with 1 μg/ml tetracycline, 200 nM AP20187, 
for 48 h. After the desired treatments had concluded, the medium was aspirated and 
replaced with fresh DMEM medium that lacked phenol red, but contained 0.5 mg/ml MTT. 
The cells were incubated at 37 °C with 5 % (v/v) CO2 at 95 % humidity for 3 h. The medium 
was aspirated and replaced with 150 μl of 4 mM HCl, 0.1% (v/v) Nonidet P-40 in isopropanol. 
The plates were covered with aluminium foil and shaken for 15 min on an orbital shaker at 
room temperature to dissolve the MTT crystals. Once this was done the absorbance was 
read at 590 nm and 690 nm (reference wavelength) using a microplate reader. 
3.3.10 Protein isolation from mammalian cell lines 
5x106 Cells were seeded as described in 3.3.4 into 9 cm adherent cell dishes. The dishes 
were incubated as described 3.3.1 overnight before treatment. 
RIPA buffer was produced on the day of protein isolation as described in (2.9). One 
PhosSTOP phosphatase inhibitor (Roche) and one Complete mini protease inhibitor cocktail
tablet (Roche) were added to 10 ml of ice-cold RIPA buffer. The RIPA buffer containing 
containing complete protease inhibitors and phosphatase inhibitors was prepaired fresh on 
the day of isolation as the inhibitors are only stable for 24 h once dissolved. 
The cells were placed on ice and the medium was aspirated and discarded. The cells were 
washed three times in 2 ml of ice-cold PBS before the addition 300 μl of ice-cold RIPA buffer. 
The cells were scraped in order to detach them from the dish. The dishes were left at an 
angle of ~45o for 5 min on ice to ensure all of the cells had been collected before being 
transferred to a 1.5 ml microcentrifuge tube and incubated for 10 min on ice to allow lysis 
to occur. The protein lysates were centrifuged at 16,000 g for 10 min at 4 oC to pellet the 
cell debris and the supernatants were transferred to fresh 1.5 ml microcentrifuge tubes. 
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3.3.11 Bio-Rad DC Protein assay 
Protein sample was diluted 1:10 in dH2O. Pipette 5 µl sample, standard including the blank, 
and buffer control into a clean, dry microtiter plate with two repeats for all samples. The 
buffer control is RIPA buffer diluted 1:10 in H2O. 25 µl Bio-Rad reagent A and 200 µl of Bio-
Rad reagent B into each well using a multichannel pipette. The microtiter plate was 
incubated at RT for 15 min with gentle shaking. Read absorbance at 750 nm in a microplate 
reader (molecular devices spectramax 190). 
3.4 Western blotting 
3.4.1 Protein electrophoresis 
Protein was isolated and concentration was measured as described in (2.2.20). We 
combined 20-30 μg of protein with 6x SDS-PAGE loading buffer and denatured at 70 oC for 
10 min before being separated by gel electrophoresis. 
The electrophoresis unit was disassembled, the glass was washed in 10% sds followed by 70 % 
ethanol. The glass slides were inserted and the unit was reassembled on a rubber base to 
prevent gel leakage. 
The following mixture was used to create a 10 % separating gel. All reagents were prepared 
on ice and degassed for 5 min during the stages below. 
Table 3.4.1.1 Separating gel mix 
Component Volume 
30 % (w/v) acrylamide, 0.8% (w/v) bisacrylamide 2.50 ml 
1 M Tris·HCl, pH 8.9 1.875 ml 
H2O 3.13 ml 
Add after degasing: 
10 % (w/v) SDS 50 μl 
10 % (w/v) ammonium persulfate 45 μl 
TEMED 10 μl 
Total 7.61 ml 
Table 3.4.1.2 Stacking gel mix  
Component Volume 
30 % (w/v) acrylamide, 0.8 % (w/v) bisacrylamide 0.34 ml 
1 M Tris·HCl, pH 6.8 0.625 ml 
H2O 1.56375 ml 
Add after degasing: 
10 % (w/v) SDS 6.25 μl 
10 % (w/v) ammonium persulfate 22.5 μl 
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TEMED 7.5 μl 
Total 2.56 ml 
5 µl of page ruler (thermo scientific) was added to the first well of the gel. 20-30 µg of total 
protein + 6x SDS-PAGE loading buffer of each protein sample was pipetted into each well. 
The gel was left to run for 1 h at 120V. 
3.4.2 Membrane semidry transfer 
The SDS-PAGE gel was removed from its casing and carefully transferred to a plastic 
container containing 1x Semi-dry Transfer Buffer (2.9) and then incubated with gentle 
shaking for 30 min. 
PDVF membrane was washed in methanol for 1 min and then incubated with gentle shaking 
for 30 min in 1x Semi-dry Transfer Buffer (2.9). 8 pieces of Whatman 3 MM paper were 
incubated with gentle shaking for 30 min 1x Semi-dry Transfer Buffer (2.9). The SDS-PAGE 
gel & PDVF membrane was placed between 8 pieces of incubated Whatman 3 MM paper.  
The surface of the anode of the semi-dry transfer unit was cleaned before assembly of the 
gel stack. 4 of the pre-soaked pieces of Whatman 3 MM paper where placed in a neat stack 
on the semi-dry transfer apparatus, a 50 ml tube was then rolled over the stack to remove 
bubbles. The incubated PDVF membrane was placed upon this stack and then the SDS gel 
was placed on top of the membrane. The remaining 4 pieces of incubated Whatman 3 MM 
paper were stacked on top of the gel. A 50 ml tube was rolled over the stack gently to 
remove bubbles. The apparatus was then set to transfer at 2 mA/cm2 for 60-75 min.  
The membrane was stored at 4°C in a 50 ml falcon tube filled with TBST (2.9). 
3.4.3 Antibody staining 
The membrane was blocked overnight with bovine serum albumin BSA 5 % (v/w) (2.9) in 4°C 
cold lab or for one hour at room temperature. The membrane was washed three times in 
Tris-buffered saline + Tween 20 TBST (2.9), then incubate in 3 ml BSA 5 % and 3 µl antibody 
(2.3), BSA was necessary for blotting of phosphorylated proteins. The membrane was 
washed in TBST for 5 min three times, then incubated in 5 % milk with a secondary antibody 
at a 1:1000 dilution. 
3.4.4 Chemiluminescence detection with luminol 
The following mixture was prepared immediately before use and kept protected from light: 
15 ml 100 mM Tris-HCL, pH 8.5 + 0.1 % (v/v) Tween 20 
75 µl 250 mM luminal 
33.3 µl 90 mM p-coumaric acid 
4.35 µl 30 % (w/w) H2O2 
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This was mixed well and protected from light. 
The membrane was washed again in TBST for 5 min three times. The membrane was gently 
dried and place in an X-ray cassette inside of a plastic cover.  
The following steps were performed in a dark room. 
1 ml of the above solution was pipetted onto the membrane. The membrane was incubated 
for 1 min at RT in the dark. A photographic film was placed on top of the plastic cover and 
membrane inside the X-ray cassette. The X-ray cassette was closed and left to expose for 
0.5-5 min. The exposed film was removed from the cassette and developed in X-ray film 
processor (Compact X4 Automatic Processor). 
3.4.5 Immunoprecipitation
Prior to protein isolation, phosphatase and protease inhibitors (Roche) were added to the 
RIPA buffer as described in section (3.3.10) 
Pre-clearing: 20 μl of Protein A-agarose beads (2.9) were centrifuged at 100 g for 2 min. The 
supernatant was pipetted and removed, the beads were then re-suspended in 100 μl of 
RIPA buffer before being centrifuged at 800 rpm for 2 min. The supernatant was pipetted 
and discarded.  
To the pre-cleared protein A-agarose beads, 250 μg of protein dissolved in 200 μl of RIPA 
buffer was added and 0.8 μg of rabbit IgG. The samples were incubated at 4 oC for 1 h whilst 
rotating at 8 rpm (Stuart rotator drive STR4). The samples were then centrifuged at 800 rpm 
for 2 min before the supernatants were transferred to fresh 1.5 ml micro-centrifuge tubes. 
5 µl of antibody specific to the protein (anti-HA) (2.3) that was being used as the “bait” 
during the assay were added to the samples and incubated overnight at 4 oC rotating at 8 
rpm. 20 μl of protein A-agarose beads were added to the protein lysates and incubated for 1 
h at 4 o C whilst rotating at 8 rpm. The samples were centrifuged at 800 rpm for 2 min 
before the supernatants were discarded. The beads were subjected to three washes in 500 
μl RIPA buffer + 0.1% NP-40. 500μl RIPA buffer were added to the protein A-agarose beads 
and centrifuged at 800 rpm for 2 min before the buffer was discarded. The protein A-
agarose beads were centrifuged a final time for 2 min at 800 rpm and any residual buffer 
was removed. 30 μl of 6x SDS-PAGE sample buffer were added to the beads, which were 
heated at 70 oC for 10 min. After this, the samples were collected via centrifugation for 15 s. 
The proteins were then separated by electrophoresis and analysed by Western blotting as 
described in (3.4.1-3.4.4).
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4. Results 
4.1 Introduction 
As discussed in the introduction, IRE1 α controls cell survival or apoptosis during 
endoplasmic reticulum stress. Given the important role of IRE1 α in cell fate it represents an 
important target for therapeutic intervention in pathogenic diabetes, cancer and other UPR-
related diseases. It is possible that IRE1 α functions are separated between its RNase and 
Kinase domains. IRE1 α protective and apoptotic signalling could be controlled through two 
distinct enzymatic domains. Inhibition of the Kinase domain whilst retaining the functioning 
RNase domain could result in only protective cell signalling preventing apoptosis. This 
hypothesis of IRE1 α domain roles means that protective signalling would only be 
therapeutic if the Kinase domain alone signalled apoptotic cell death. 
Therefore, it was decided to investigate the activity of the Kinase domain by characterising a 
kinase active RNase deficient Fv2E IRE1 α mutant. To investigate this possibility, I used an 
Fv2E IRE1 α mutant, and using site-directed mutagenesis to create point mutations in key 
RNase residues before transfecting into Flip-In T-REx HEK293 cells to be transcribed and 
translated. 
As discussed in the introduction I plan on using an Fv2E chimera to cause IRE1 α activation 
in insolation from ATF6 and PERK. Alongside this system I plan to transfect our mutants into 
Flip-in T-REx cells. Flip-in cells contain a stably integrated FRT site at a transcriptionally 
active genomic locus (Thermofisher.com, 2018), this will allow the generation of stable cell 
lines that can express the Fv2E IRE1 α in high levels (Thermofisher.com, 2018). Although this 
expression is desirable overexpression could result in the unintentional activation of our 
mutant, because of this I will control the gene expression though T-REx system 
(Thermofisher.com, 2018) as described in Figure 1.9.1. Flip-in T-REx Hek 293 cell lines have 
shown low basal expression of the target gene in control samples, while in the presence of 
tetracycline show high expression of the target gene (Thermofisher.com, 2018) 
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Figure 4.1.1, Diagram of Fv2E IRE1 α in media containing tetracycline or tetracycline and AP20187 (B-B homodimer). 
Normal media should have very low expression of IRE1 α and no dimerization of IRE1 α. Media containing tetracycline 
should overexpress the Fv2E IRE1 α mutant with little to no dimerization. In media containing tetracycline and AP20187 (B-
B homodimer) should overexpress Fv2E IRE1α and dimerise resulting in P-IRE1 α. In WT IRE1 α dimerization occurs in the 
presence of unfolded protein. AP20187 will cause dimerization of the luminal domains of the Fv2E IRE1α mutant as seen in 
WT cells under ER stress. 
As described in Figure 4.1.1, our test will involve two treatments and a control for each 
mutant. By testing the three samples I will be able to determine if cell viability is affected by 
the tetracycline treatment, or the overexpression of the Fv2E IRE1 α mutant induction by 
tetracycline treatment. By comparing the results from control, tetracycline and tetracycline 
+ AP20187 (B-B homodimer) I hope to be able to characterise the mutations to IRE1 α 
mitigating the possible effects of tetracycline and AP20187 on the results. 
By characterising a Kinase active RNase deficient mutant to discern if the kinase domain 
alone is capable of causing apoptosis. If this is possible then it would indicate that the two 
enzymatic domain functions are distinct and that the TRAF2 apoptotic signalling does not 
require influence from the RNase domain. 
4.2 Expression of Fv2E IRE1 α in Flip-in T-REx HEK 293 cell lines 
Three other Fv2E IRE1 α mutants (K907A, N906A and H910N) had already been created and 
acquired for this project, these mutations in yeast caused Kinase active RNase deficient 
mutants (Tirasophon, 2000) and therefore were chosen given the high likelihood of 
producing the desired characterises in mammalian cells. We extracted the plasmids from E. 
coli using the protocol from (3.2.10) and transfected in to Flp-In T-Rex HEK293 cells using 
(3.3.5) protocol. We tested the three mutants for expression of Fv2E IRE1 α and used two 
control cell cultures WT and K599A Fv2E IRE1 α. K599A Fv2E IRE1 α is a mutant that stably 
produced in HEK 293 cell that are Kinase and RNase dead. The three mutant cultures and 
two control cultures were split as described in (3.3.4) using sterile technique. 
33
Figure 4.2.1, Flp-In T-Rex HEK293 Fv2E-IRE1α mutants were treated with tetracycline (1 μg/ml) and AP20187 (200 nM) for 
48 h. Cells were lysed and lysate was extracted as described in (3.3.10) for Western blotting. Cell lysate was Western 
blotted as described in (3.4) with anti-HA antibody on two separate Western blots.
Through Western blotting we confirmed successful transfection of HEK 293 cells with Fv2E 
IRE1 α N906A and H910N as seen in Figure 4.2.1. We noted that the K906A Fv2E IRE1 α
mutant culture although antibiotic resistant did not produce protein upon exposure of 
tetracycline. Sequencing of the Fv2E IRE1 α K907A plasmid as described in (2.10) showed 
that the sequence differed from the WT Fv2E IRE1 α plasmid. Inspection of the Fv2E IRE1 α
sequence map, revealed that the K907A mutant plasmid did not contain the Fv2E region 
required for expression of the protein. 
4.3 RNase domain activity 
The RNase domain of IRE1 α cleaves XBP1 and the ligase complex Rtc2B ligates the exons
(Kosmaczewski et al., 2018) into its active form XBP1s for intracellular signalling (Tsuru et al., 
2018), however we do not know how long this process takes. To determine the RNase 
activity of the Fv2E IRE1 α mutants we first determined the time frame for WT Fv2E IRE1 α 
XBP1 splicing to XBP1s through an XBP1 splicing assay as described in (3.3.8).  
Figure 4.3.1, Flp-In T-Rex HEK293 Fv2E-IRE1 α WT was treated with tetracycline (1 μg/ml) for 24h before exposure to 
tetracycline (1 μg/ml) and AP20187 (200 nM) as described in above. RNA was extracted as described in (3.3.6) and 
transformed in to cDNA as described in (3.3.7). The RNA was tested through an XBP1 splicing assay explained in (3.3.8). No 
housekeeping control was used; therefore no numerical comparisons could be completed on this image.  
It was noted that XBP1 splicing was seen within the first 15 minutes, and possibly earlier 
after exposure. For the testing of the three mutants a tetracycline (1 μg/ml) for 24 h before 
exposure to tetracycline (1 μg/ml) and AP20187 (200 nM) for 24h was chosen for maximum 
splicing. It was noted that the 24h time point likely shows reduced expressions due to cell 
death caused by IRE α activation by AP20187 leading to reduced protein present in tested 
samples. 
I tested the RNase activity of the two Fv2E IRE1 α mutants and used two control cell cultures 
WT and K599A Fv2E IRE1 α. The three mutant cultures and two control cultures WT and 
K599A were split as described in (3.3.4) using sterile technique.  
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Figure 4.3.2, Flp-In T-Rex HEK293 Fv2E-IRE1 α mutants were treated with tetracycline (1 μg/ml) for 24h before exposure to 
tetracycline (1 μg/ml) and AP20187 (200 nM) for 24h. RNA was extracted as described in (3.3.6) and transformed in to 
cDNA as described in (3.3.7). The RNA was tested through an XBP1 splicing assay explained in (3.3.8). Analysis was 
performed using LI-COR image studio software. 
As seen in Figure 4.3.2, XBP1 splicing is clearly visible in the WT Fv2E IRE1 α and partial 
splicing in the H910N mutant with 24h tetracycline and 24h tetracycline and AP20187 
exposure. We noted that the N906A mutant did not have XBP1 Splicing. We decided that 
the H910N Fv2E IRE1 α mutant still retained RNase activity. We concluded that the N906A 
Fv2E IRE1 α mutant RNase splicing was repressed through the point mutations and 
proceeded to characterise its Kinase activity as seen in chapter 3.5.   
4.4 Kinase activity 
Of the three mutated plasmids tested, one culture possessed RNase dead Fv2E IRE1 α 
expression. We decided to test the kinase activity of the Fv2E IRE1 α N906A mutant against 
the Kinase activity of the WT Fv2E IRE1 α. 
Figure 4.4.1, Flp-In T-Rex HEK293 Fv2E-IRE1 α WT and N906A were treated with tetracycline (1 μg/ml) and AP20187 (200 
nM) for 48h. Cell lysate was extracted as described in (3.3.10) for Western blotting. Cell lysate was Western blotted as 
described in (3.4) with anti-p-IRE1 α (S724).
As can be seen the Western Blotting Figure 4.4.1, for phosphorylated IRE1 α both WT and 
N906A Fv2E IRE1 α showed the presence of phosphorylation of serine 724 IRE1 α in the 
presence of tetracycline and Ap20187 for 48h. Weak bands of phosphorylated IRE1 α were 
seen in the presence of just tetracycline for both WT and N906A Fv2E IRE1 α. We therefore 
have characterised the N906A Fv2E IRE1 α mutant as RNase deficient in chapter 4.3 and 
Kinase active in chapter 4.4. 
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4.5 Cell death 
We had confirmed that the N906A Fv2E IRE1 α mutant was RNase deficient in chapter 4.3 
and that it had retained its kinase activity in chapter 4.4. I decided to test N906A Fv2E IRE1 
α mutant for apoptotic activity or cell death. To test the viability of the N906A Fv2E IRE1 α 
mutant when exposed to tetracycline & AP20187, we used an MTT assay for cell viability as 
described in (3.3.9) against WT Fv2E IRE1 α previously shown to have reduced viability upon 
exposure to tetracycline & AP20187 (Nishitoh, 2002, Watson, PhD thesis). 
Figure 4.5.1, Flp-In T-Rex HEK293 Fv2E-IRE1 α WT and N906A were treated with tetracycline (1 μg/ml) and AP20187 (200 
nM) for 48 h each in a 96 well plate. Three plate repeats were performed, each cell line was cultured in a 96 well plate.  
Each plate was split so that 8 wells in each plate were used to zero the microplate reader and 22 wells were used for each 
treatment. Each plate were treated with DMEM medium containing 0.5 mg/ml MTT for 3 h as described in (3.3.9). After 
treatment, wavelength absorption were taken at 590 nm and 690 nm (reference wavelength) using a microplate reader as 
detailed in (3.3.9).
Readings were taken at 590 nm as it corresponds to the wavelength on the dissolved dye 
absorption of electromagnetic radiation formed by oxidation of active cells. We created a 
comparison of MTT viability results from WT and N906A Fv2E IRE1 α. We tested both cell 
lines to see if cell viability was affected by treatment of tetracycline (1 μg/ml), as seen in 
Figure 4.5.1, tetracycline treatment alone did not affect cell viability. We noted that no 
relevant change in cell viability was detected when N906A Fv2E mutant was exposed to 
tetracycline and AP20187 for 48h unlike WT Fv2E IRE1 α that had a significant decrease in 
cell viability. Figure 4.5.1, shows that N906A Fv2E IRE1 α viability is not affected by 
treatment with tetracycline and AP20187. This proposes that the Kinase activity of IRE1 α 
signalling alone does not lead to apoptotic signalling.  
4.6 WT & N906A Fv2E IRE1 α phosphorylation of JNK 
To investigate this model and the reasons behind the viability of the N906A Fv2E IRE1 α 
exposed to tetracycline and AP20187 we chose to investigate phosphorylation of JNK as a 
marker for apoptosis (Dhanasekaran and Reddy, 2008). P-JNK is marker known for cell stress 
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and has been shown to be activated due to IRE1 α signalling, therefore we used it as a 
marker for apoptotic signalling capability of N906A Fv2E IRE1 α. 
Figure 4.6.1, Flp-In T-Rex HEK293 Fv2E-IRE1 α WT and N906A were treated with tetracycline (1 μg/ml) and AP20187 (200 
nM) for 48h. Cell lysate was extracted as described in (3.3.10) for Western blotting. Cell lysate was Western blotted as 
described in (3.4) with anti-P-JNK. 
The Western blot of Phospho-JNK with WT Fv2E IRE1 α and N906A Fv2E IRE1 α mutants 
showed a strong band with the WT when exposed to tetracycline and AP20187 for 48 h as 
seen in Figure 4.6.1. The N906A mutant did show some activation of P-JNK activation in the 
control, tetracycline, tetracycline and AP20187. The downstream signalling of N906A Fv2E-
IRE1 α through P-JNK seems to show stronger activation under tetracycline and AP20187, 
given the results of chapter 4.5 we conclude that this signalling is not sufficient to induce 
apoptosis. 
4.7 PARP-1 Cleavage 
To further investigate the results of chapter 4.5 and 4.5 we explored other markers for 
apoptosis. We chose to investigate poly(ADP-ribose) polymerase (PARP-1). PARP-1 cleavage 
is a useful hallmark of apoptosis (Chaitanya, Alexander and Babu, 2010), it is cleaved by 
DEVD-ase caspases activated during apoptosis. 
To obtain data on the downstream signalling of Fv2E-IRE1 α, Flp-In T-Rex HEK293 Fv2E-IRE1 
α WT and N906A cells were treated with tetracycline (1 μg/ml) or tetracycline (1 μg/ml) 
AP20187 (200 nM) for 48 h. Protein lysate was extracted as described in (3.3.10) then 
separated via gel electrophoresis for Western blotting against an anti-PARP-1 antibody as 
described in (3.4). 
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Figure 4.7.1, Flp-In T-Rex HEK293 Fv2E-IRE1 α WT and N906A were treated with tetracycline (1 μg/ml) and AP20187 (200 
nM) for 48h. Cell lysate was extracted as described in (2.2.20) for Western blotting. Cell lysate was Western blotted as 
described in (3.4) with anti-PARP1. 
Western blotting results in Figure 4.7.1, showed clear cleavage in WT Fv2E IRE1 α exposed 
to tetracycline and AP20187 while the N906A mutant had no clear cleavage band although I 
was unable to produce a clear image. We were unable to clearly characterise the PARP-1 
response of N906A; it is possible that cleavage combined with impurities in the gel could 
explain the unclear results seen for Figure 4.7.1, Fv2E IRE1 α N906A with tetracycline + 
AP20187 treatment. 
To explain these results, I needed to investigate the upstream signalling of PARP-1 and JNK. I 
decided to investigate IRE1 α kinase domain interaction with TRAF 2. 
4.8 Immunoprecipitation of TRAF2 
To understand IRE1 α kinase domain we must look at its interaction with the kinase domain-
mediated signalling cascade adaptor protein TRAF2 (Urano et al., 2000). As can be seen in 
Figure 1.7.1, phosphorylated IRE1 α apoptotic pathway is believed to originate with its 
interaction with TRAF2 leading to activation of ASK1 and phosphorylation of JNK as seen in 
Chapter 4.4 (Kadowaki and Nishitoh, 2013). This apoptotic pathway leads to the activation 
of key apoptotic cell death protein markers such as PARP-1 cleavage investigated in Chapter 
4.7 (Chaitanya, Alexander and Babu, 2010). To investigate this interaction, we must 
understand the interaction between N906A Fv2E IRE1 α and TRAF2, to do this we explored 
isolating TRAF2 with IRE1 α from cell lysate immediately after extraction through 
immunoprecipitation. 
To investigate the lack of apoptotic cell death we tested Fv2E IRE1 α N906A interaction with 
TRAF2 through immunoprecipitation which has previously been used to detect IRE1 α – 
TRAF2 interactions. Flp-In T-Rex HEK293 Fv2E-IRE1 α WT and N906A were treated with 
tetracycline (1 μg/ml) or tetracycline (1 μg/ml) and AP20187 (200 nM) for 48 h with a 
control with no treatment. Immunoprecipitation was performed as described in chapter 
3.4.5. Cell lysate for this immunoprecipitation experiment was extracted from the HEK293 
cells as described in Chapter 3.3.10. We determined the concentration of protein before 
adding 250 µg of protein to 20 µl of protein A-agarose beads for pre-clearing immediately 
after extraction. The reasoning behind the immediate immunoprecipitation after extraction 
of the cell lysate is to prevent the interaction of TRAF2 and IRE1 α after extraction from the 
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cell. We exposed the newly extracted cell lysate to the Protein A-agarose beads, we did this 
immediately to prevent artificial interactions caused by freeze thaw cycles. I did this initially 
to remove unspecific integrators, with the beads or protein A. Pre-cleared lysate was 
incubated with fresh protein A-agarose beads before repeated washing. The washed protein 
A-agarose beads were then Western blotted as described in Chapter 3.4 with an anti-TRAF2 
antibody. 
Figure 4.8.2, Immunoprecipitation of TRAF2 using an HA.tag antibody and HA.tag Fv2E IRE1 α. Protein A agarose beads are 
mixed with anti-HA tag antibodies, the anti-HA antibodies bind to the protein A agarose beads. IRE1 α contains HA.tag 
sequence that binds to anti-HA antibody Protein A complex. Protein lysate is mixed then subsequently washed after 
centrifugation, proteins bound to the agarose beads are concentrated in the remaining solution. Active IRE1 α interacts and 
forms a complex with TRAF2 resulting in TRAF2 presence in lysate through Immunoprecipitation. 
We initially used a rabbit anti-TRAF2 primary antibody with an anti-rabbit secondary 
antibody. Western blotting through this method was unreadable due to background 
interference. I decided that the HA.tag rabbit primary antibody for immunoprecipitation as 
shown in Figure 4.8.2, was not denatured in the heating step as described in (3.4) and 
bound to the secondary antibody during Western blotting. I used a mouse anti-TRAF2 
primary antibody in combination with an anti-mouse secondary antibody to solve this issue. 
Repeated anti-TRAF2 Western blotting of HA.tag immunoprecipitation failed to produce a 
band for TRAF2 at 55 kDa in the Fv2E WT/N906A IRE1 α exposed to tetracycline and 
AP20187 for 48h. Explanation of these results is discussed in 5.8. 
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5. Discussion 
5.1 Investigation of Fv2E K907A IRE1 α lack of expression in HEK 293 T-REx cells 
The Fv2E K907A, N906A and H910N IRE1 α mutants were obtained from another lab. Given 
that the transfection of pcDNA5/FRT/TO-Fv2E-IRE1 α K907A this mutant did not produce a 
Fv2E IRE1 α K907A in HEK293 cells we decided to investigate this through sequencing. 
Sequencing of K907A plasmid as described in chapter 2.10 showed that the plasmid 
contained the ERN1 gene but not the Fv2E domains. This region is responsible for the 
mutant’s cytosolic nature. This mutant protein would be induced by tetracycline would not 
be cytoplasmic and therefore would not be detected by Western blotting of the cell lysate. 
5.2 Assessment of RNase domain activity through XBP1 splicing assays 
As the XBP1 splicing assay control demonstrated that the Fv2E IRE1 α chimera retained its 
RNase activity (Figure 4.3.1). I chose the 48 h AP20187 treatment time period as the control 
XBP1 splicing assay did not show any un-spliced XBP1. 
By using this time point I found that H910N Fv2E IRE1 α mutant retained partial activity of 
the RNase domain as seen in Figure 4.3.2, Although substitution of a key amino acid did 
affect the expression this site alone does not seem to completely remove the RNase activity 
of Fv2E IRE1 α chimera although this was predicted in Han et al., 2009. As the mutant 
retained activity it is likely that this amino acid plays a large role in IRE1 α RNase activity but 
further mutations would be required to remove the activity completely. The K907A Fv2E 
IRE1 α mutant did not show XBP1 splicing in Figure 4.3.2, although this was explained in 
chapter 5.1 as this mutant did not produce the cytosolic protein and the Fv2E chimera 
RNase activity is still to be characterised. 
The N906A mutant as seen in Figure 4.3.2, did not show the presence of XBP1s in the XBP1 
splicing assay. Therefore, the N906A mutation removes the RNase activity beyond 
detectable levels and was suitable for further testing of in this project. Given that the N906A 
mutation created a Kinase active and RNase deficient mutant IRE1 α, this area of the protein 
could be a viable site for creating future RNase deficient mutants. Future experiments could 
attempt to create mutants with key mutations in this area (836-961 aa) to create a Fv2E 
IRE1 α mutant to explore this possibility. As will be discussed in chapter 5.8 mutations can 
interfere with p-IRE1 α interaction with TRAF2 and the Kinase apoptotic pathway, it is 
possible that this region has a higher probability of producing RNase deficient mutant but 
could prevent the Kinase domain interaction with TRAF2 therefore these mutants might not 
confirm whether the kinase domain alone can cause apoptosis.  
5.3 Apoptotic cell death 
The MTT test establishes cell viability, the test doesn’t distinguish the pathway through cell 
death occurs. Although N906 Fv2E IRE1 α remain viable implies that the kinase signalling 
pathway has not been activated or that it is not causing apoptosis in this mutant. Therefore, 
to investigate why apoptosis is not occurring in the N906A Fv2E IRE1 α mutant we must 
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investigate the mechanisms surrounding IRE1 α Kinase mediated apoptosis. To do this we 
looked at P-JNK a downstream signaller of TRAF2 (Nishitoh, 2002) and PARP-1 a recognised 
signal protein (Chaitanya, Alexander and Babu, 2010) for apoptosis to investigate the 
mechanisms of the N906A Fv2E IRE1 α mutant. An alternative hypothesis to explain these 
results is that apoptotic signalling of IRE1 α is dependent on the RNase domain. Han et al. 
2009 also showed that in kinase active, RNase deficient mutant did not lead to cell death in 
INS-1 cells with K907A & N906A mutant, chapter 4.5 shows that this fate also occurs in HEK 
293 cells for N906A mutants. 
5.4 Immunoprecipitation of TRAF2 
Given issues with reagents for immunoprecipitation of TRAF2 with IRE1 α, the issue is 
unlikely to reside with the antibody’s as anti-IRE1 α produced results in chapter 4.2 Figure 
4.2.1. Issues with TRAF2 Western blotting were overcome through replacement of the 
primary and secondary antibody as well as changing species for primary antibody, Western 
blotting of whole cell lysate for TRAF2 confirmed bands therefore there remains two 
possibilities for the remaining issue, these are explained below. 
One possibility for the failure to detect TRAF2 in the extract could be that the TRAF2 or the 
Fv2E IRE1α TRAF2 complex is removed from the agarose beads through the successive 
washing steps as described in chapter 3.4.5. The procedure has been successful in other 
research by our lab, further (Moser, Chan and Fritzler, 2009) optimisation of the procedure 
could have yielded retention of TRAF2 in the extract and detection in anti-TRAF2 Western 
blotting. Preparing samples with different numbers of washing steps then Western blotting 
would find the number of washes that bound TRAF2 is retained while removing non bound 
TRAF2. 
The second possibility is that the issue resides with the agarose beads, given that the 
reagent is stored at +4˚C (recommended storage conditions 1 year) it was likely to have 
expired. The affinity of the beads to antibodies since purchase could have reduced resulting 
in the loss of the TRAF2-pIRE1 α complex through the washing steps resulting in the lack of 
TRAF2 detected in the Western blotting. It is possibly that replacement of the reagent could 
have resolved whether Fv2E N906A IRE1 α interacts with TRAF2. Replacement of this 
reagent with a newer system for immunoprecipitation such as magnetic agarose beads, 
could have increased the yield of TRAF2 through washing steps. 
5.5 IRE1 α phosphorylation 
Although we were unable to confirm if N906A Fv2E IRE1 α interacted with TRAF2 to explain 
the results of 4.6, it is possible that the Fv2E IRE1 α N906A does interact with TRAF2 without 
leading to apoptosis. Given that P-IRE1 α antibody only indicates phosphorylation of serine 
724 IRE1 α, other sites on IRE α might remain un-phosphorylated in the N906A mutant. 
Although IRE1 α phosphorylation site (serine 724) was phosphorylated, this proteins kinase 
domain may not have the same characteristics as the wild type due to the level of 
phosphorylation.   
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To explore this possibility, we could measure the level of phosphorylation of Fv2E IRE1 α 
against the WT. To do this we could use radioactive labelled phosphorus through ATP as 
used in Han et al., 2009. This experiment could be explored to explain the lack of apoptosis 
in N906A Fv2E IRE1 α seen in 4.5. Given that in Han et al. 2009 kinase active, RNase dead 
mutants in INS-1 cells did not show apoptosis; a likely explanation from this paper is that 
kinase active, RNase dead mutants HEK 293 cells do not cause apoptosis. To investigate this 
theory we should explore immunoprecipitation, this experiment would confirm any 
interactions between N906A Fv2E IRE1 α and TRAF2. Further investigation of kinase dead, 
RNase dead mutants interaction with TRAF2 could confirm that mutations in the kinase 
domain prevent interaction and activation of the TRAF2 pathway. This would explain the 
Western blotting results seen in chapter 4.4 and Figure 4.4.1, for kinase activity, although 
the mutant would bind to anti-p-IRE1 α through Western blotting as antibody only binds to 
one phosphorylation site. If only this phosphorylation site is active other phosphorylation 
sites required for kinase activity with TRAF2 might remain un-phosphorylated, preventing 
the apoptotic signalling and resulting in the lack of apoptosis seen in chapter 4.5. 
5.6 Conclusion 
If a kinase active RNase IRE1 α mutant retained its apoptotic function, given the loss of the 
protective actions of the RNase domain the percentage of cell death should be higher than 
that seen in the WT Fv2E IRE1 α Figure 4.5.1. Although we were unable to measure the 
interaction between N906A IRE1α and TRAF2; given that we have seen activation of p-JNK 
and possible cleavage of PARP-1 the affinity of the IRE1 α-TRAF2 interaction might be 
sufficient to cause apoptotic signalling without sufficient intensity to cause apoptosis. 
Additionally, as discussed in chapter 5.5 partial phosphorylation of IRE1 α could lead to the 
results seen. If the level of phosphorylation affects the activation and signalling of apoptosis 
via TRAF2. The level of activation of a partially phosphorylated IRE1 α could show some p-
JNK activation but no PARP-1 cleavage therefore showing no noticeable cell death 
explaining the results of Figure 4.5.1, MTT test for cell viability. Given the results in Han et al. 
2009 with INS-1 cells apoptosis caused by IRE1 α pathway could require interaction from an 
active IRE1 α RNase domain to cause apoptosis. Although this research was inconclusive 
creation of further kinase active RNase dead mutants might reveal the true characterisation 
of the IRE1 α kinase and RNase domain roles in eukaryotic cells. 
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7. Appendix 
7.1 Solutions for protein work  
Table 7.1 Solutions for protein work 
 Solutions Protocol 
 Electrotransfer buffer 
 4.20 g NaHCO3 
1.59 g Na2CO3  
Add 5 l H2O  
 RIPA Buffer 
 0.5 ml 1 M Tris·HCl pH 8.0 
0.3 ml 5 M NaCl 
0.1 ml Triton X-100 
0.5 ml 10% (w/v) sodium deoxycholate 
0.1 ml 10% (w/v) sodium dodecyl sulphate (SDS) Add 
H2O to 10 ml 
Add protease/phosphatase inhibitor as required. 
 10x Semi-Dry Transfer Buffer  
 73.19 g Glycine 
60.6 g Tris-Base  
Dissolve in ~350 ml H2O  
Add DI H2O to 500 ml  
1x Semi-Dry Transfer Buffer 
50 ml 10 x semi-Dry transfer buffer 25 ml Methanol 
Add DI H2O to 500 ml 
TBST 
24.2 g Tris base 80g NaCl 1 ml Tween 20 Dissolve in 
~800 ml pH ~ 7.6  
Add H2O to 1 l  
6 x SDS-PAGE sample buffer  
3.50 ml 1 M Tris·HCl 3.78 g glycerol 1.00 g SDS 500 μl 
10 g/l bromophenol blue 200 μl β-mercaptoethanol  
Add H2O to 10 ml  
10 x SDS-PAGE running buffer  
144.13 g glycine 30.03 g Tris 10.00 g SDS 
Add H2O to ~ 900 ml, stir until completely dissolved, 
then add H2O to 1 l. 
Stripping solution  
1g SDS 
350 μl β-mercaptoethanol Dissolve in ~40 ml H2O Add 
H2O to 50 ml 
TBST + 5% (w/v) skimmed milk 
powder 
5 g milk powder  
Dissolve in 100 ml TBST 
TBST + 5% (w/v) BSA  0.5 g BSA Dissolve in 10 ml TBST  
0.5 mg/ml MTT (3-[4,5-
Dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide; 
Thiazolyl blue) 
Per 1 ml H2O: 
0.5 mg MTT 
Protein A-Agarose Beads Purchased from Santa Cruz Biotechnology (#sc-2001)  
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7.2 Solutions for DNA work  
Table 7.2 Solutions for DNA work 
Solution Protocol 
2 mM dNTPs 
 910 μl H2O 
10 μl 100 mM Tris·HCl (pH 8.0) 20 μl 100 mM dATP 
20 μl 100 mM dCTP 
20 μl 100 mM dGTP 
20 μl 100 mM dTTP 
50x TAE 
242 g Tris 57.1 ml HOAc 37.2 g Na2EDTA·2H2O Dissolve in ~800 
ml H2O Add H2O to 1 l pH ~ 8.5  
10x TE (pH 8.0)  
400 ml 1 M Tris·HCl (pH 8.0) 80 ml 0.5 M EDTA Add H2O to 4 l 
Autoclave  
7.3 Solutions for RNA work  
Table 7.3 Solutions used for RNA work 
Solution Protocol 
DEPC-H2O  
1 mL DEPC 
1 l sterile H2O  
Autoclave.  
2 mM dNTPs  
910 μl DEPC treated water 
10 μl 100 mM Tris·HCl (pH 8.0) in DEPC 
treated water.  
20 μl 100 mM dATP 
20 μl 100 mM dCTP 
20 μl 100 mM dGTP  
20 μl 100 mM dTTP  
7.4 Plasmids Table  
Table 7.4 List of plasmids used 
Name Source 
pcDNA5/FRT/TO-Fv2E-K907A- C'IRE1 α  
 Dr. David Cox & Dr. Martin Schrӧder, 
Durham University  
 pcDNA5/FRT/TO-Fv2E-N906A- C'IRE1 α 
Dr. David Cox & Dr. Martin Schrӧder, 
Durham University 
pcDNA5/FRT/TO-Fv2E-H910A- C'IRE1 α  
 Dr. David Cox & Dr. Martin Schrӧder, 
Durham University  
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7.5 Solutions for bacterial work  
Table 7.5 Solutions used for bacterial work 
Solution Protocol 
SOC Broth (per Liter) 
20 g tryptone 
5 g Yeast extract 
0.5 g NaCl 
2.5 ml 1 M KCl 
Adjust pH to 7 with 10 M NaOH 
Make up to 990 ml with dH2O 
AUTOCLAVE 
After autoclaving add: 
10 ml filter sterilised 1 M MgCl2 
20 ml filter sterilised 1 M glucose 
2 mM dNTPs 
910 μl H2O 
10 μl 100 mM Tris·HCl (pH 8.0) 20 μl 100 mM dATP 
20 μl 100 mM dCTP 
20 μl 100 mM dGTP 
20 μl 100 mM dTTP 
50x TAE 
242 g Tris 57.1 ml HOAc 37.2 g Na2EDTA·2H2O Dissolve in 
~800 ml H2O Add H2O to 1 l pH ~ 8.5 
10x TE (pH 8.0) 
400 ml 1 M Tris·HCl (pH 8.0) 80 ml 0.5 M EDTA Add H2O to 4 l 
Autoclave 
